Cellectar Biosciences

@CellectarBio

Creating the Next Generation of Targeted Cancer Therapies

Vrijeme pridruživanja: ožujak 2016.

Tweetovi

Blokirali ste korisnika/cu @CellectarBio

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @CellectarBio

  1. : According to , new cases of , and are expected to account for 10% of the estimated 1,762,450 new cases diagnosed in the U.S. in 2019. For more info, visit

    Poništi
  2. 4. velj

    Do you know some of the key signs and symptoms of having cancer? Check out the infographic below or visit for more information.

    Poništi
  3. 4. velj

    More than one third of cancer cases can be prevented and another third can be cured if detected early and treated properly.

    Poništi
  4. 3. velj

    The answer is ~32,270! Thank you to everyone who voted!

    Prikaži ovu nit
    Poništi
  5. 31. sij

    According to , how many new cases of Multiple Myeloma will be diagnosed in the United States in 2020? For more information about Multiple Myeloma and other cancer types, visit

    Prikaži ovu nit
    Poništi
  6. 30. sij

    Do you have our upcoming clinical data call on your calendar yet? If not, click the link for more information about the call: For more info about , visit

    Poništi
  7. 28. sij

    From the interview with Dr. Laura Finn: “What I like about this drug, and especially in multiple myeloma, is its safety and its very low incidence of side effects.”

    Poništi
  8. 27. sij

    : Cellectar Biosciences to Host a Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020

    Poništi
  9. 22. sij

    “...drop the payload internally, inside of the cell. It’s the ultimate Trojan Horse, if you will, when you think about our delivery platform.”

    Poništi
  10. 21. sij

    Incredible article from “This is the first time [an increase in leukemia] has been shown to be statistically significant.”

    Poništi
  11. 21. sij

    Check out our updated deck () and put our upcoming clinical data call () on your calendars!

    Poništi
  12. 21. sij

    Thanks for following us !

    Poništi
  13. 20. sij

    For more information about Cellectar visit: For articles about , click the following: l

    Poništi
  14. 17. sij

    : Cellectar Receives Orphan Drug Designation for in Lymphoplasmacytic Lymphoma (LPL): For more information about LPL, visit :

    Poništi
  15. 15. sij

    Are you at or today? We would love to connect! Check out our updated deck () and put our upcoming clinical data call () on your calendars!

    Poništi
  16. 14. sij

    : CEO Jim Caruso presented yesterday afternoon at Biotech Showcase to give an update about Cellectar's PDC platform and lead product candidate :

    Poništi
  17. 14. sij

    Click the following link to see a playback of our presentation at the this afternoon:

    Prikaži ovu nit
    Poništi
  18. 13. sij

    We are excited to be at today with an updated corporate deck. Check it out:

    Prikaži ovu nit
    Poništi
  19. 13. sij

    Cellectar's CEO Jim Caruso will present TODAY at in Yosemite A at 4:00pm PT. Don’t miss it! (Webcast will be available online after the presentation).

    Poništi
  20. 10. sij
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·